Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jan 31, 2015

Filed with the SEC on Mar 13, 2015 and accepted by EDGAR at Mar 13, 2015, 17:21 ET.

Share

Management's discussion and analysis

As filed, 12,000 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

This following information specifies certain forward-looking statements of our management. Forward-looking statements are statements that estimate the happening of future events and are not based on historical fact. Forward-looking statements may be identified by the use of forward-looking terminology, such as “may”, “shall”, “could”, “expect”, “estimate”, “anticipate”, “predict”, “probable”, “possible”, “should”, “continue”, or similar terms, variations of those terms or the negative of those terms. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict, and no representation, guaranty, or warranty is to be inferred from those forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements.

Forward-looking statements include, but are not limited to, the following:

  • Statements relating to our future business and financial performance;
  • Statements relating to future preclinical studies, clinical trials and regulatory approvals of our products;
  • Statements relating to our competitive position; and
  • Other material future developments that you may take into consideration.

Results of Operations for the Nine Months Ended January 31, 2015 and 2014

The Company (in this Report “Company,” “PharmaCyte Biotech,” “we,” “us” and “our” refer to PharmaCyte Biotech, Inc. and, where appropriate, its subsidiaries), successfully completed the acquisition of a biotechnology company through its acquisition of Bio Blue Bird AG (“Bio Blue Bird”) effective June 25, 2013. Bio Blue Bird is now a wholly-owned subsidiary of the Company that holds the exclusive worldwide licensing rights to the use of the Cell-in-a-Box® live cell encapsulation technology for treating pancreatic cancer.

We are a biotechnology company bringing to market scientifically derived products designed to improve the health, condition and well-being of those who use them. Our focus for the present and immediate future is in the oncology and diabetes arenas. We are in the process of developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box®. We plan to use this unique and patented technology as a platform on which to build treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes.

Our treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live-cells, which convert ifosfamide into its active or “cancer-killing” form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer.

We are also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of abdominal cancers using the Cell-in-a-Box® technology.

In addition, the Company is developing treatments for cancer based upon the chemical constituents of the Cannabis plant, knows as cannabinoids. In doing so, the Company is examining ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides the Company the opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.

We are currently preparing for a Phase 2b clinical trial with our pancreatic cancer treatment in patients with advanced, inoperable pancreatic cancer that will be conducted in Australia. That clinical trial is expected to commence in the third quarter of 2015. We are also preparing for clinical trials of that same treatment to study its effects on major symptoms associated with pancreatic cancer. The first two clinical trials related to the symptoms associated with pancreatic cancer involve the unbearable pain from advanced pancreatic cancer and the accumulation of malignant ascites fluid that usually occurs with this disease. These clinical trials are expected to commence in the third quarter of 2015 and will be conducted in the United States. A preclinical study on ascites has been completed in the United States and a follow-up study is currently underway.

On November 24, 2014, the Company entered into a Licensing Agreement (“Cannabis Licensing Agreement”) with Austrianova Singapore Pte Ltd ("Austrianova Singapore"), a subsidiary of SG Austria Private Limited and an entity partially owned by us, providing the Company with an exclusive world-wide royalty-bearing license (with the right to sublicense) to use the Cell-in-a-Box® live cell encapsulation technology and trademark with genetically modified non-stem cells which are designed to activate cannabinoids for research, development and commercialization of treatments for diseases and medical conditions. The Cannabis Licensing Agreement is effective as of December 1, 2014. The license royalty rate is 10% on direct sales and 20% on sales by a sub-licensee, with an initial license fee of $2 million due and payable by the Company to Austrianova Singapore by no later than June 30, 2015. The Company has paid Austrianova Singapore $800,000 of the initial license fee and will make periodic monthly payments of the balance in amounts to be agreed upon between the parties prior to each such payment being made. In addition, the following milestone payments are due as indicated:

Amount Event
$100,000 Within thirty days of the beginning the first pre-clinical experiments using the encapsulated cells;
$500,000 Within thirty days after enrolment of a human in the first clinical trial;
$800,000 Within thirty days after enrolment of a human in the first Phase 3 clinical trial; and
$1,000,000 Within ninety days after obtaining the first Marketing Authorization or equivalent according to the country of origin.

Selling, General and Administrative Expenses

For the nine months ended January 31, 2015, sales and marketing expense decreased by $94,100 to $230,500 from $324,600 for the same period in the prior year. The decrease is a result of our efforts to have a more cost effective marketing strategy.

For the nine months ended January 31, 2015, research and development expenses increased by $621,567 from $0 for the same period in the prior year. The increase is a result of the Company’s efforts to research medical uses of the licenses acquired in its acquisitions.

For the nine months ended January 31, 2015, compensation expense increased by $3,863,312 to $5,298,372, as compared to $1,435,060 for the same period in the prior year. The increase is a result of additional stock options being issued for compensation during the current period.

For the nine months ended January 31, 2015, legal and professional fees increased by $609,840 to $850,571 from $240,731 for the same period in the prior year. The increase is attributed to an increase in attorney fees.

General and administrative expenses during the nine months ended January 31, 2015 compared to the nine months ended January 31, 2014, increased by $1,754,193 to $2,284,143 as compared to $529,950 in the prior period. The increase can be attributed to increased travel expense, investor relations, warrants issued to consultants that were valued at $100,000 and other consulting service expense. This expense also includes the $297,500 non-cash expense from the issuance of common stock to Lincoln Park in accordance with the provisions of a Mutual Termination and Release Agreement releasing all parties from certain obligation under a Stock Purchase Agreement between the parties.

During the nine months ended January 31, 2015, our net loss decreased by $3,676,662 to $7,106,547, as compared to $10,783,209 in the prior period. The decrease in net loss can mainly be attributed to the decrease in losses from conversion of preferred stock and settlement of debt netted with an increase in compensation expense associated with stock options issued during the current period.

Liquidity and Capital Resources

For the nine months ended January 31, 2015, the Company used cash of $2,968,672 in operations, used cash of $500,000 from investing activities and provided cash of $811,018 from financing activities.

On May 28, 2014, we entered into a financial advisory, offering and at the market offering engagement agreement (“Chardan Agreement”), with Chardan Capital Markets, LLC (“Chardan”) pursuant to which Chardan agreed to use its reasonable best efforts to act as our sales agent in connection with the sale of common stock in “at the market” or privately negotiated transactions of up to $50 million, depending upon market conditions and at our sole discretion. In connection with such transactions, we agreed to pay Chardan: (i) a cash fee of 3% of the gross proceeds from the sale of any shares of common stock sold in an “at-the-market” offering and (ii) a cash fee of 7% of the aggregate sales price of any distinct blocks of common stock sold under the Chardan Agreement, plus five-year warrants representing 5% of the number of shares of common stock sold. In addition, we agreed to reimburse certain expenses of Chardan in an amount not to exceed $15,000.

On October 17, 2014, we filed a Prospectus (“Prospectus”) with the United States Securities and Exchange Commission (“SEC”) pursuant to which we disclosed that we may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants or units having a maximum aggregate offering price of $50,000,000. We also explain that when we decide to sell a particular class or series of securities, we would provide specific terms of the offered securities in a Prospectus Supplement.

On November 12, 2014, we filed a Prospectus Supplement (“Prospectus Supplement”) with the SEC. The Prospectus Supplement described the terms of the Chardan Agreement and added to and updated information contained in the Prospectus. We also described that the sales of our common stock, if any, under the Prospectus Supplement and the Prospectus would be made by any method permitted that is deemed an “at the market” offering as defined in Rule 415 under the Securities Act of 1933, as amended (“Securities Act”), including by means of ordinary brokers’ transactions at market prices, in block transactions or as otherwise agreed by Chardan and us. Under this arrangement, Chardan will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices.

On December 2, 2014, we amended the Prospectus Supplement with the SEC. In the amended Prospectus Supplement, we disclosed that the sales of our common stock under the Prospectus Supplement may include sales at a fixed price as agreed by Chardan and us. Under this arrangement, Chardan will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices.

Controls and procedures

As filed, 2,532 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company's management, including the Chief Executive Officer, President and General Counsel and interim Chief Financial Officer of the Company, as its principal and financial executive officer (Principal Officer”), evaluated the effectiveness of the Company's “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (“Exchange Act”). Based upon this evaluation, the Principal Officer has concluded that, as of January 31, 2015, the Company's disclosure controls and procedures were effective for the purpose of ensuring that the information required to be disclosed in the reports that the Company files or submits to the Securities and Exchange Commission (“SEC”) pursuant to the Exchange Act is recorded, processed, summarized and reported within the time period specified by the SEC’s rules and forms and is accumulated and communicated to the Company's management, including its Principal Officer, as appropriate to allow timely decisions regarding required disclosures.

Although the management of the Company, including the Principal Officer, believes that our disclosure controls and internal controls currently provide reasonable assurance that our desired control objectives have been met, management does not expect that our disclosure controls or internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Risk factors

As filed, 2,188 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In addition to the other information set forth in this Report, you should carefully consider the factors discussed in Part I, Item 1A., “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended April 30, 2014 (as amended) and in the Prospectus Supplement. The information set forth in these Reports could materially affect the Company’s business, financial position and results of operations. There are no material changes from the risk factors set forth in Part I, Item 1A, “Risk Factors,” of our Annual Report on Forms 10-K for the fiscal year ended April 30, 2014 and in the Prospectus Supplement, other than as set forth below:

Our Recent Entry into a Significant Licensing Agreement Could Adversely Affect our Liquidity and our Ability to Execute our Research and Development Strategy.

On November 24, 2014, the Company entered into the Cannabis Licensing Agreement. The use of our existing capital resources to make payments under the Cannabis Licensing Agreement will accelerate our need for additional capital to continue our operations. Failure to obtain such capital or generate such operating revenues would have an adverse impact on our financial position, operations and ability to continue as a going concern unless we are able to extend the payment provisions of the Cannabis Licensing Agreement. There can be no assurance that any such extension, or additional private or public financing (including debt or equity financing), will be available as needed or if available, on terms favorable to us. Additionally, any future equity financing may be dilutive to stockholders’ present ownership levels and such additional equity securities may have rights, preferences, or privileges that are senior to those of our existing common stock. Furthermore, debt financing, if available, may require payment of interest and potentially involve restrictive covenants that could impose limitations on the flexibility of our ability to operate. The payment terms of the Cannabis Licensing Agreement taken in conjunction with any difficulty or failure to successfully obtain additional funding may jeopardize our ability to continue our business and operations.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-01-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2014-11-01 to 2015-01-31$0us-gaap:Revenues
Revenue9 months2014-05-01 to 2015-01-31$0us-gaap:Revenues
Cost of revenue3 months2014-11-01 to 2015-01-31$0us-gaap:CostOfRevenue
Cost of revenue9 months2014-05-01 to 2015-01-31$0us-gaap:CostOfRevenue
Gross profit3 months2014-11-01 to 2015-01-31$0us-gaap:GrossProfit
Gross profit9 months2014-05-01 to 2015-01-31$0us-gaap:GrossProfit
Research and development3 months2014-11-01 to 2015-01-31$273.8kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2014-05-01 to 2015-01-31$621.6kus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative9 months2014-05-01 to 2015-01-31$100.0kus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2014-11-01 to 2015-01-31−$1.5mus-gaap:OperatingIncomeLoss
Operating income9 months2014-05-01 to 2015-01-31−$9.3mus-gaap:OperatingIncomeLoss
Interest expense3 months2014-11-01 to 2015-01-31$1.5kus-gaap:InterestExpense
Interest expense9 months2014-05-01 to 2015-01-31$6.2kus-gaap:InterestExpense
Net income3 months2014-11-01 to 2015-01-31−$1.5mus-gaap:NetIncomeLoss
Net income9 months2014-05-01 to 2015-01-31−$7.1mus-gaap:NetIncomeLoss
Basic EPS3 months2014-11-01 to 2015-01-31$0.00us-gaap:EarningsPerShareBasic
Basic EPS9 months2014-05-01 to 2015-01-31−$0.01us-gaap:EarningsPerShareBasic
Operating cash flow9 months2014-05-01 to 2015-01-31−$3.0mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash and equivalentsAt period end2015-01-31$958.8kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2015-01-31$997.0kus-gaap:AssetsCurrent
Total assetsAt period end2015-01-31$6.6mus-gaap:Assets
Current liabilitiesAt period end2015-01-31$378.5kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2015-01-31$378.5kus-gaap:Liabilities
Shareholders' equityAt period end2015-01-31$6.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001019687-15-000953. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.